Table 2. . Rodent models for brain tumors.
Induction | Species/strain | Source | Pathology | Applications | Ref. |
---|---|---|---|---|---|
Cell line inoculation | C57BL/6 | GL26 cells | GBM/ependymoblastoma | DC vaccines engineered to express IL-12. Treg depletion. Metronomic chemotherapy. Combined conditionally cytotoxic and immunostimulatory gene therapy |
[1–5] |
GL26.1 cells | GBM/ependymoblastoma | Immunological checkpoint blockade. Antitumor DC vaccines + Treg blockade with anti-CD25 antibody. Peptide vaccinations + TGF-β neutralizing antibody | [6–10] | ||
CT-2A cells | Anaplastic astrocytoma | Genetically modified T cells targeting EGFRvIII and IL13Rα2 | [11,12] | ||
VM-Dk | SMA-560 cells | Anaplastic astrocytoma | Overexpression of soluble CD70 ligand. Inhibition of TGF-β signaling. EGFRvIII CAR-modified T-cell therapy. Antitumor DC vaccines |
[13–17] | |
B6D2F1 | 4C8 cells | Oligodendroglioma, astrocytoma | Cationic liposome–DNA complexes. HSV vaccines encoding IL-12 | [18,19] | |
Cell line inoculation | LEWIS | CNS-1 cells | GBM | Antitumor DC vaccines. TLR agonists. Metronomic chemotherapy. Combined conditionally cytotoxic and immunostimulatory gene therapy | [20–23] |
FISHER 344 | F98 cells | GBM | Combined conditionally cytotoxic and immunostimulant gene therapy. Cellular vaccinations + GM-CSF. Upregulation of costimulatory molecules |
[5,24,25] | |
RG2 cells | Anaplastic astrocytoma | Gene therapy-mediated delivery of chemokines and cytokines. Metronomic chemotherapy | [26,27] | ||
9L cells | Gliosarcoma | Gene therapy-mediated delivery of proinflammatory cytokines. Tumor vaccination + TGF-β inhibition | [5,28,29] | ||
Genetic engineering | GFAP-Cre | Lentiviral-mediated knock down of NF1 and p53 | Mesenchymal GBM | [30] | |
p53 KO | Lentiviral-mediated delivery of Ras and AKT | GBM | [31] | ||
C57BL/6FVB/nBalb/c | Sleeping beauty transposon plasmids encoding for NRAS, AKT, SV40-LgT, EGFRvIII, shp53 | Grade III astrocytoma, GBM | [32,33] | ||
p53, Arf or Ink4a-Arf KO Gtv-a mice | RCAS-mediated delivery of PDGF | GBM/oligodendroglioma | TAM targeting with a CSF-1R inhibitor | [34,35] | |
Ntva-a mice | RCAS-mediated delivery of PDGF, Ras and AKT | GBM | [36] | ||
Ink4a-Arf KO Gtv-a mice | RCAS-mediated delivery of Ras and AKT | GBM/gliosarcoma | [37] | ||
Genetic engineering | Sprague Dawley | Retroviral-mediated delivery of PDGF | GBM | [38] | |
Lentiviral-mediated delivery of PDGF, H-RAS, AKT | GBM | [39] |
DC: Dendritic cell; GBM: Glioblastoma; HSV: Herpes simplex virus; RCAS: Retroviral vectors derived from the SR-A strain of Rous sarcoma virus; TAM: Tumor-associated microglia.